{"id":"tailored-antithrombotic-strategy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombotic events"}]},"_chembl":{"chemblId":"CHEMBL1201202","moleculeType":"Oligosaccharide","molecularWeight":"1508.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tailored antithrombotic strategy represents a precision medicine approach to thrombotic disease management, where antithrombotic agents (anticoagulants, antiplatelet drugs, or combinations) are selected and optimized based on patient-specific factors including genetic polymorphisms, renal function, drug interactions, bleeding and clotting risk scores, and comorbidities. This individualized strategy aims to maximize efficacy while minimizing adverse events compared to one-size-fits-all dosing protocols.","oneSentence":"A personalized anticoagulation approach that tailors antithrombotic therapy selection and dosing based on individual patient characteristics, biomarkers, and clinical risk factors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:10:56.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombotic disease prevention and treatment (various indications including atrial fibrillation, venous thromboembolism, acute coronary syndrome)"}]},"trialDetails":[{"nctId":"NCT07084051","phase":"NA","title":"Improve Medication Adherence Among Stroke Survivors in Rural Kentucky","status":"COMPLETED","sponsor":"Hend Mansoor","startDate":"2025-07-24","conditions":"Stroke (CVA) or Transient Ischemic Attack","enrollment":4},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT05948969","phase":"NA","title":"Transform CV Risk in Diabetes","status":"UNKNOWN","sponsor":"American College of Cardiology","startDate":"2023-09-01","conditions":"Type 2 Diabetes","enrollment":750},{"nctId":"NCT04502017","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"Texas Cardiac Arrhythmia Research Foundation","startDate":"2020-08-05","conditions":"Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tailored antithrombotic strategy","genericName":"Tailored antithrombotic strategy","companyName":"Duk-Woo Park, MD","companyId":"duk-woo-park-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Researchers are studying a tailored antithrombotic strategy, known as CLOT-LESS, which aims to reduce antithrombotic medication in patients who have undergone left atrial appendage closure for stroke prevention. The strategy involves using medications such as apixaban and standard-dose DOACs, which are oligosaccharide-based anticoagulants like fondaparinux.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}